{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:10:33Z","timestamp":1792782633846,"version":"4.5.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T00:00:00Z","timestamp":1573430400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T00:00:00Z","timestamp":1573430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["UG1DA013727"],"award-info":[{"award-number":["UG1DA013727"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["UG1DA015831"],"award-info":[{"award-number":["UG1DA015831"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["UG1DA020024"],"award-info":[{"award-number":["UG1DA020024"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["UG1DA013714"],"award-info":[{"award-number":["UG1DA013714"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["U10DA013045"],"award-info":[{"award-number":["U10DA013045"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["K24DA038240"],"award-info":[{"award-number":["K24DA038240"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["K23DA042935"],"award-info":[{"award-number":["K23DA042935"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["T32DA035200"],"award-info":[{"award-number":["T32DA035200"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["K01DA036739"],"award-info":[{"award-number":["K01DA036739"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"crossref","award":["K23AA025399"],"award-info":[{"award-number":["K23AA025399"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"crossref","award":["K12HD055885"],"award-info":[{"award-number":["K12HD055885"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Department of Health and Human Services","award":["HHSN271201200017C"],"award-info":[{"award-number":["HHSN271201200017C"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00213-019-05384-z","type":"journal-article","created":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T01:03:01Z","timestamp":1573434181000},"page":"479-490","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder"],"prefix":"10.1007","volume":"237","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6961-4399","authenticated-orcid":false,"given":"Rachel L.","family":"Tomko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel L.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlyn O.","family":"Hood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda K.","family":"Gilmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin A.","family":"McClure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay M.","family":"Squeglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee L.","family":"McRae-Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan C.","family":"Sonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,11]]},"reference":[{"key":"5384_CR1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.drugalcdep.2019.01.002","volume":"197","author":"D Anand","year":"2019","unstructured":"Anand D, Paquette C, Bartuska A, Daughters SB (2019) Substance type moderates the longitudinal association between depression and substance use from pre-treatment through a 1-year follow-up. Drug Alcohol Depend 197:87\u201394","journal-title":"Drug Alcohol Depend"},{"key":"5384_CR2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1037\/0033-295X.111.1.33","volume":"111","author":"TB Baker","year":"2004","unstructured":"Baker TB, Piper ME, McCarthy DE, Majeskie MR, Fiore MC (2004) Addiction motivation reformulated: an affective processing model of negative reinforcement. Psychol Rev 111:33\u201351","journal-title":"Psychol Rev"},{"key":"5384_CR3","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1037\/0033-2909.107.2.238","volume":"107","author":"PM Bentler","year":"1990","unstructured":"Bentler PM (1990) Comparative fit indexes in structural models. Psychol Bull 107:238\u2013246","journal-title":"Psychol Bull"},{"key":"5384_CR4","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1037\/0033-2909.88.3.588","volume":"88","author":"PM Bentler","year":"1980","unstructured":"Bentler PM, Bonett DG (1980) Significance tests and goodness of fit in the analysis of covariance structures. Psychol Bull 88:588","journal-title":"Psychol Bull"},{"key":"5384_CR5","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4088\/JCP.13m08454","volume":"75","author":"M Berk","year":"2014","unstructured":"Berk M, Dean OM, Cotton SM, Jeavons S, Tanious M, Kohlmann K, Hewitt K, Moss K, Allwang C, Schapkaitz I, Robbins J, Cobb H, Ng F, Dodd S, Bush AI, Malhi GS (2014) The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 75:628\u2013636","journal-title":"J Clin Psychiatry"},{"key":"5384_CR6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12916-019-1257-1","volume":"17","author":"M Berk","year":"2019","unstructured":"Berk M et al (2019) A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo. BMC Med 17:18","journal-title":"BMC Med"},{"key":"5384_CR7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0022-3999(01)00296-3","volume":"52","author":"I Bjelland","year":"2002","unstructured":"Bjelland I, Dahl AA, Haug TT, Neckelmann D (2002) The validity of the Hospital Anxiety and Depression Scale: an updated literature review. J Psychosom Res 52:69\u201377","journal-title":"J Psychosom Res"},{"key":"5384_CR8","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1176\/appi.ajp.158.12.2033","volume":"158","author":"GB Bovasso","year":"2001","unstructured":"Bovasso GB (2001) Cannabis abuse as a risk factor for depressive symptoms. Am J Psychiatry 158:2033\u20132037","journal-title":"Am J Psychiatry"},{"key":"5384_CR9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/BF02294361","volume":"52","author":"H Bozdogan","year":"1987","unstructured":"Bozdogan H (1987) Model selection and Akaike\u2019s information criterion (AIC): the general theory and its analytical extensions. Psychometrika 52:345\u2013370","journal-title":"Psychometrika"},{"key":"5384_CR10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1037\/0021-843X.112.3.393","volume":"112","author":"AJ Budney","year":"2003","unstructured":"Budney AJ, Moore BA, Vandrey RG, Hughes JR (2003) The time course and significance of cannabis withdrawal. J Abnorm Psychol 112:393","journal-title":"J Abnorm Psychol"},{"key":"5384_CR11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/10550490802408936","volume":"18","author":"KM Carpenter","year":"2009","unstructured":"Carpenter KM, McDowell D, Brooks DJ, Cheng WY, Levin FR (2009) A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. Am J Addict 18:53\u201364","journal-title":"Am J Addict"},{"key":"5384_CR12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00127-002-0541-z","volume":"37","author":"C-Y Chen","year":"2002","unstructured":"Chen C-Y, Wagner FA, Anthony JC (2002) Marijuana use and the risk of major depressive episode. Soc Psychiatry Psychiatr Epidemiol 37:199\u2013206","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"5384_CR13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/14737175.2018.1407242","volume":"18","author":"GD Colpo","year":"2018","unstructured":"Colpo GD, Leboyer M, Dantzer R, Trivedi MH, Teixeira AL (2018) Immune-based strategies for mood disorders: facts and challenges. Expert Rev Neurother 18:139\u2013152","journal-title":"Expert Rev Neurother"},{"key":"5384_CR14","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1369-1600.2007.00095.x","volume":"13","author":"ZD Cooper","year":"2008","unstructured":"Cooper ZD, Haney M (2008) Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor. Addict Biol 13:188\u2013195","journal-title":"Addict Biol"},{"key":"5384_CR15","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.addbeh.2008.02.001","volume":"33","author":"JR Cornelius","year":"2008","unstructured":"Cornelius JR, Chung T, Martin C, Wood DS, Clark DB (2008) Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence. Addict Behav 33:1500\u20131505","journal-title":"Addict Behav"},{"key":"5384_CR16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.drugalcdep.2010.05.010","volume":"112","author":"JR Cornelius","year":"2010","unstructured":"Cornelius JR et al (2010) Double-blind fluoxetine trial in comorbid MDD\u2013CUD youth and young adults. Drug Alcohol Depend 112:39\u201345","journal-title":"Drug Alcohol Depend"},{"key":"5384_CR17","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jad.2018.04.054","volume":"235","author":"C Cuttler","year":"2018","unstructured":"Cuttler C, Spradlin A, McLaughlin RJ (2018) A naturalistic examination of the perceived effects of cannabis on negative affect. J Affect Disord 235:198\u2013205","journal-title":"J Affect Disord"},{"key":"5384_CR18","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1521-0391.2011.00148.x","volume":"20","author":"E Dakwar","year":"2011","unstructured":"Dakwar E et al (2011) A comparison of independent depression and substance-induced depression in cannabis-, cocaine-, and opioid-dependent treatment seekers. Am J Addict 20:441\u2013446","journal-title":"Am J Addict"},{"key":"5384_CR19","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/aje\/kwq096","volume":"172","author":"R de Graaf","year":"2010","unstructured":"de Graaf R et al (2010) Early cannabis use and estimated risk of later onset of depression spells: epidemiologic evidence from the population-based World Health Organization World Mental Health Survey Initiative. Am J Epidemiol 172:149\u2013159","journal-title":"Am J Epidemiol"},{"key":"5384_CR20","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1046\/j.1360-0443.2003.00437.x","volume":"98","author":"L Degenhardt","year":"2003","unstructured":"Degenhardt L, Hall W, Lynskey M (2003) Exploring the association between cannabis use and depression. Addiction 98:1493\u20131504","journal-title":"Addiction"},{"key":"5384_CR21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jad.2014.10.006","volume":"172","author":"D Feingold","year":"2015","unstructured":"Feingold D, Weiser M, Rehm J, Lev-Ran S (2015) The association between cannabis use and mood disorders: a longitudinal study. J Affect Dis 172:211\u2013218","journal-title":"J Affect Dis"},{"key":"5384_CR22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.psychres.2017.02.027","volume":"251","author":"D Feingold","year":"2017","unstructured":"Feingold D, Rehm J, Lev-Ran S (2017) Cannabis use and the course and outcome of major depressive disorder: a population based longitudinal study. Psychiatry Res 251:225\u2013234","journal-title":"Psychiatry Res"},{"key":"5384_CR23","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.bbr.2019.02.025","volume":"364","author":"J Fernandes","year":"2019","unstructured":"Fernandes J, Gupta GL (2019) N-acetylcysteine attenuates neuroinflammation associated depressive behavior induced by chronic unpredictable mild stress in rat. Behav Brain Res 364:356\u2013365","journal-title":"Behav Brain Res"},{"key":"5384_CR24","doi-asserted-by":"crossref","first-page":"e457","DOI":"10.4088\/JCP.15r09984","volume":"77","author":"BS Fernandes","year":"2016","unstructured":"Fernandes BS, Dean OM, Dodd S, Malhi GS, Berk M (2016) N-acetylcysteine in depressive symptoms and functionality: a systematic review and meta-analysis. J Clin Psychiatry 77:e457\u2013e466","journal-title":"J Clin Psychiatry"},{"key":"5384_CR25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.drugalcdep.2013.01.013","volume":"132","author":"L Florez-Salamanca","year":"2013","unstructured":"Florez-Salamanca L, Secades-Villa R, Budney AJ, Garcia-Rodriguez O, Wang S, Blanco C (2013) Probability and predictors of cannabis use disorders relapse: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend 132:127\u2013133","journal-title":"Drug Alcohol Depend"},{"key":"5384_CR26","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/NMD.0b013e31819db6fe","volume":"197","author":"S Glasner-Edwards","year":"2009","unstructured":"Glasner-Edwards S, Marinelli-Casey P, Hillhouse M, Ang A, Mooney LJ, Rawson R (2009) Depression among methamphetamine users: association with outcomes from the Methamphetamine Treatment Project at 3-year follow-up. J Nerv Ment Dis 197:225\u2013231","journal-title":"J Nerv Ment Dis"},{"issue":"4","key":"5384_CR27","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/jamapsychiatry.2018.4500","volume":"76","author":"Gabriella Gobbi","year":"2019","unstructured":"Gobbi G, Atkin T, Zytynski T, Wang S, Askari S, Boruff J, Ware M, Marmorstein N, Cipriani A, Dendukuri N, Mayo N (2019) Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood: a systematic review and meta-analysis. JAMA psychiatry 76(4):426\u2013434","journal-title":"JAMA Psychiatry"},{"key":"5384_CR28","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1176\/appi.ajp.2012.12010055","volume":"169","author":"KM Gray","year":"2012","unstructured":"Gray KM et al (2012) A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry 169:805\u2013812","journal-title":"Am J Psychiatry"},{"key":"5384_CR29","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.drugalcdep.2017.04.020","volume":"177","author":"KM Gray","year":"2017","unstructured":"Gray KM et al (2017) A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend 177:249\u2013257","journal-title":"Drug Alcohol Depend"},{"key":"5384_CR30","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1176\/appi.ajp.2015.15070907","volume":"173","author":"D Hasin","year":"2016","unstructured":"Hasin D et al (2016) Prevalence and correlates of DSM-5 cannabis use disorder, 2012-2013: findings from the National Epidemiologic Survey on Alcohol and Related Conditions\u2013III. Am J Psychiatry 173:588\u2013599","journal-title":"Am J Psychiatry"},{"key":"5384_CR31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1089\/can.2017.0024","volume":"2","author":"C Hindocha","year":"2017","unstructured":"Hindocha C, Freeman TP, Curran HV (2017) Anatomy of a joint: comparing self-reported and actual dose of cannabis and tobacco in a joint, and how these are influenced by controlled acute administration. Cannabis Cannabinoid Res 2:217\u2013223","journal-title":"Cannabis Cannabinoid Res"},{"issue":"6","key":"5384_CR32","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/mp.2011.82","volume":"17","author":"J Hirvonen","year":"2011","unstructured":"Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, Morse C, Pike VW, Volkow ND, Huestis MA, Innis RB. (2012) Reversible and regionally selective downregulation of brain cannabinoid CB 1 receptors in chronic daily cannabis smokers. Molecular psychiatry. 17(6):642\u201349","journal-title":"Molecular Psychiatry"},{"key":"5384_CR33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jsat.2017.07.012","volume":"81","author":"YI Hser","year":"2017","unstructured":"Hser YI, Mooney LJ, Huang D, Zhu Y, Tomko RL, McClure E, Chou CP, Gray KM (2017) Reductions in cannabis use are associated with improvements in anxiety, depression, and sleep quality, but not quality of life. J Subst Abus Treat 81:53\u201358","journal-title":"J Subst Abus Treat"},{"key":"5384_CR34","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1007\/s00213-017-4725-3","volume":"234","author":"J Jacobus","year":"2017","unstructured":"Jacobus J et al (2017) Changes in marijuana use symptoms and emotional functioning over 28-days of monitored abstinence in adolescent marijuana users. Psychopharmacol 234:3431\u20133442","journal-title":"Psychopharmacol"},{"key":"5384_CR35","doi-asserted-by":"crossref","first-page":"65","DOI":"10.31887\/DCNS.2016.18.1\/pkalivas","volume":"18","author":"BC Kalivas","year":"2016","unstructured":"Kalivas BC, Kalivas PW (2016) Corticostriatal circuitry in regulating diseases characterized by intrusive thinking. Dialogues Clin Neurosci 18:65\u201376","journal-title":"Dialogues Clin Neurosci"},{"key":"5384_CR36","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.drugalcdep.2017.09.032","volume":"181","author":"BT Kerridge","year":"2017","unstructured":"Kerridge BT et al (2017) Predictors of treatment utilization and barriers to treatment utilization among individuals with lifetime cannabis use disorder in the United States. Drug Alcohol Depend 181:223\u2013228","journal-title":"Drug Alcohol Depend"},{"key":"5384_CR37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.drugalcdep.2012.10.015","volume":"130","author":"SS Khan","year":"2013","unstructured":"Khan SS, Secades-Villa R, Okuda M, Wang S, Perez-Fuentes G, Kerridge BT, Blanco C (2013) Gender differences in cannabis use disorders: results from the National Epidemiologic Survey of Alcohol and Related Conditions. Drug Alcohol Depend 130:101\u2013108","journal-title":"Drug Alcohol Depend"},{"key":"5384_CR38","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0893-133X(00)00195-0","volume":"24","author":"GF Koob","year":"2001","unstructured":"Koob GF, Le Moal M (2001) Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacol 24:97\u2013129","journal-title":"Neuropsychopharmacol"},{"key":"5384_CR39","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1111\/add.13912","volume":"112","author":"AM Leventhal","year":"2017","unstructured":"Leventhal AM, Cho J, Stone MD, Barrington-Trimis JL, Chou CP, Sussman SY, Riggs NR, Unger JB, Audrain-McGovern J, Strong DR (2017) Associations between anhedonia and marijuana use escalation across mid-adolescence. Addiction 112:2182\u20132190","journal-title":"Addiction"},{"key":"5384_CR40","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/add.12108","volume":"108","author":"FR Levin","year":"2013","unstructured":"Levin FR et al (2013) A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders. Addiction 108:1084\u20131094","journal-title":"Addiction"},{"key":"5384_CR41","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1017\/S0033291713001438","volume":"44","author":"S Lev-Ran","year":"2014","unstructured":"Lev-Ran S, Roerecke M, Le Foll B, George TP, McKenzie K, Rehm J (2014) The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychol Med 44:797\u2013810","journal-title":"Psychol Med"},{"key":"5384_CR42","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.drugalcdep.2010.08.008","volume":"113","author":"JJ Mariani","year":"2011","unstructured":"Mariani JJ, Brooks D, Haney M, Levin FR (2011) Quantification and comparison of marijuana smoking practices: blunts, joints, and pipes. Drug Alcohol Depend 113:249\u2013251","journal-title":"Drug Alcohol Depend"},{"key":"5384_CR43","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s40263-014-0142-x","volume":"28","author":"EA McClure","year":"2014","unstructured":"McClure EA, Gipson CD, Malcolm RJ, Kalivas PW, Gray KM (2014a) Potential role of N-acetylcysteine in the management of substance use disorders. CNS Drugs 28:95\u2013106","journal-title":"CNS Drugs"},{"key":"5384_CR44","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.cct.2014.08.011","volume":"39","author":"EA McClure","year":"2014","unstructured":"McClure EA et al (2014b) Achieving cannabis cessation -- evaluating N-acetylcysteine treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network. Contemp Clin Trials 39:211\u2013223","journal-title":"Contemp Clin Trials"},{"key":"5384_CR45","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.drugalcdep.2018.07.018","volume":"192","author":"EA McClure","year":"2018","unstructured":"McClure EA, Baker NL, Sonne SC, Ghitza UE, Tomko RL, Montgomery L, Babalonis S, Terry GE, Gray KM (2018) Tobacco use during cannabis cessation: use patterns and impact on abstinence in a National Drug Abuse Treatment Clinical Trials Network study. Drug Alcohol Depend 192:59\u201366","journal-title":"Drug Alcohol Depend"},{"key":"5384_CR46","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.drugalcdep.2015.08.013","volume":"156","author":"AL McRae-Clark","year":"2015","unstructured":"McRae-Clark AL et al (2015) Buspirone treatment of cannabis dependence: a randomized, placebo-controlled trial. Drug Alcohol Depend 156:29\u201337","journal-title":"Drug Alcohol Depend"},{"key":"5384_CR47","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/ajad.12324","volume":"25","author":"AL McRae-Clark","year":"2016","unstructured":"McRae-Clark AL, Baker NL, Gray KM, Killeen T, Hartwell KJ, Simonian SJ (2016) Vilazodone for cannabis dependence: a randomized, controlled pilot trial. Am J Addict 25:69\u201375","journal-title":"Am J Addict"},{"issue":"1","key":"5384_CR48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1891\/0889-8391.25.1.31","volume":"25","author":"Jane Metrik","year":"2011","unstructured":"Metrik J, Kahler CW, McGeary JE, Monti PM, Rohsenow DJ (2011) Acute effects of marijuana smoking on negative and positive affect. J Cogn Psychother 25(1):31\u201346","journal-title":"Journal of Cognitive Psychotherapy"},{"key":"5384_CR49","doi-asserted-by":"crossref","unstructured":"Nielsen S, Gowing L, Sabioni P, Le Foll B (2019) Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev (1): CD008940","DOI":"10.1002\/14651858.CD008940.pub3"},{"key":"5384_CR50","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.drugalcdep.2011.09.007","volume":"121","author":"MM Norberg","year":"2012","unstructured":"Norberg MM, Mackenzie J, Copeland J (2012) Quantifying cannabis use with the timeline followback approach: a psychometric evaluation. Drug Alcohol Depend 121:247\u2013252","journal-title":"Drug Alcohol Depend"},{"key":"5384_CR51","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jpsychores.2012.10.010","volume":"74","author":"S Norton","year":"2013","unstructured":"Norton S, Cosco T, Doyle F, Done J, Sacker A (2013) The Hospital Anxiety and Depression Scale: a meta confirmatory factor analysis. J Psychosom Res 74:74\u201381","journal-title":"J Psychosom Res"},{"key":"5384_CR52","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jad.2012.11.059","volume":"148","author":"LR Pacek","year":"2013","unstructured":"Pacek LR, Martins SS, Crum RM (2013) The bidirectional relationships between alcohol, cannabis, co-occurring alcohol and cannabis use disorders with major depressive disorder: results from a national sample. J Affect Disord 148:188\u2013195","journal-title":"J Affect Disord"},{"key":"5384_CR53","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.0006-341X.2001.00120.x","volume":"57","author":"W Pan","year":"2001","unstructured":"Pan W (2001) Akaike\u2019s information criterion in generalized estimating equations. Biometrics 57:120\u2013125","journal-title":"Biometrics"},{"key":"5384_CR54","first-page":"63","volume":"6","author":"DM Penetar","year":"2012","unstructured":"Penetar DM, Looby AR, Ryan ET, Maywalt MA, Lukas SE (2012) Bupropion reduces some of the symptoms of marihuana withdrawal in chronic marihuana users: a pilot study. Subst Abuse 6:63\u201371","journal-title":"Subst Abuse"},{"key":"5384_CR55","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/978-981-10-5311-5_13","volume-title":"The therapeutic use of N-acetylcysteine (NAC) in medicine","author":"G Powell","year":"2019","unstructured":"Powell G, McClure EA, Foster Olive M, Gipson CD (2019) Clinical treatment of addictive disorders with N-acetylcysteine. In: Frye RE, Berk M (eds) The therapeutic use of N-acetylcysteine (NAC) in medicine. Springer, Singapore, pp 219\u2013233"},{"key":"5384_CR56","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3109\/00952990.2016.1164711","volume":"43","author":"L Richter","year":"2017","unstructured":"Richter L, Pugh BS, Ball SA (2017) Assessing the risk of marijuana use disorder among adolescents and adults who use marijuana. Am J Drug Alcohol Abuse 43:247\u2013260","journal-title":"Am J Drug Alcohol Abuse"},{"key":"5384_CR57","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2174\/1871527314666150529144655","volume":"14","author":"DJ Roberts-Wolfe","year":"2015","unstructured":"Roberts-Wolfe DJ, Kalivas PW (2015) Glutamate transporter GLT-1 as a therapeutic target for substance use disorders. CNS Neurol Disord Drug Targets 14:745\u2013756","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"5384_CR58","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.drugalcdep.2018.01.009","volume":"186","author":"AL Sarvet","year":"2018","unstructured":"Sarvet AL, Wall MM, Keyes KM, Olfson M, Cerda M, Hasin DS (2018) Self-medication of mood and anxiety disorders with marijuana: higher in states with medical marijuana laws. Drug Alcohol Depend 186:10\u201315","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"5384_CR59","doi-asserted-by":"crossref","first-page":"53","DOI":"10.26828\/cannabis.2019.01.005","volume":"2","author":"Claudia Salazar","year":"2019","unstructured":"Salazar CA, Tomko RL, Akbar SA, Squeglia LM, McClure EA. (2019) Medical cannabis use among adults in the southeastern United States. Cannabis. 2(1):53","journal-title":"Cannabis"},{"issue":"2","key":"5384_CR60","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40429-017-0143-1","volume":"4","author":"Nicolas J. Schlienz","year":"2017","unstructured":"Schlienz NJ, Budney AJ, Lee DC, Vandrey R. (2017) Cannabis withdrawal: A review of neurobiological mechanisms and sex differences. Current addiction reports. 4(2):75\u201381","journal-title":"Current Addiction Reports"},{"key":"5384_CR61","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1477-7525-1-29","volume":"1","author":"RP Snaith","year":"2003","unstructured":"Snaith RP (2003) The Hospital Anxiety and Depression Scale. Health Qual Life Outcomes 1:29\u201329","journal-title":"Health Qual Life Outcomes"},{"key":"5384_CR62","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-1-4612-0357-5_3","volume-title":"Measuring alcohol consumption: psychosocial and biological methods","author":"LC Sobell","year":"1992","unstructured":"Sobell LC, Sobell MB (1992) Timeline follow-back: a technique for assessing self-report ethanol consumption. In: Allen J, Litten RZ (eds) Measuring alcohol consumption: psychosocial and biological methods. Humana Press, Totowa, pp 41\u201372"},{"key":"5384_CR63","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1521-0391.2009.00015.x","volume":"19","author":"SC Sonne","year":"2010","unstructured":"Sonne SC, Nunes EV, Jiang H, Tyson C, Rotrosen J, Reid MS (2010) The relationship between depression and smoking cessation outcomes in treatment-seeking substance abusers. Am J Addict 19:111\u2013118","journal-title":"Am J Addict"},{"key":"5384_CR64","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drugalcdep.2017.12.005","volume":"185","author":"LM Squeglia","year":"2018","unstructured":"Squeglia LM, Tomko RL, Baker NL, McClure EA, Book GA, Gray KM (2018) The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial. Drug Alcohol Depend 185:17\u201322","journal-title":"Drug Alcohol Depend"},{"key":"5384_CR65","unstructured":"Steiger JH (1980) Statistically based tests for the number of common factors. In: The annual meeting of the Psychometric Society, Iowa City, p 1980"},{"key":"5384_CR66","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1017\/S0033291706008361","volume":"36","author":"FS Stinson","year":"2006","unstructured":"Stinson FS, Ruan WJ, Pickering R, Grant BF (2006) Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. Psychol Med 36:1447\u20131460","journal-title":"Psychol Med"},{"key":"5384_CR67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2017.09.035","volume":"182","author":"RL Tomko","year":"2018","unstructured":"Tomko RL, Baker NL, McClure EA, Sonne SC, McRae-Clark AL, Sherman BJ, Gray KM (2018a) Incremental validity of estimated cannabis grams as a predictor of problems and cannabinoid biomarkers: evidence from a clinical trial. Drug Alcohol Depend 182:1\u20137","journal-title":"Drug Alcohol Depend"},{"key":"5384_CR68","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.addbeh.2018.05.014","volume":"85","author":"RL Tomko","year":"2018","unstructured":"Tomko RL, Gilmore AK, Gray KM (2018b) The role of depressive symptoms in treatment of adolescent cannabis use disorder with N-Acetylcysteine. Addict Behav 85:26\u201330","journal-title":"Addict Behav"},{"key":"5384_CR69","first-page":"30","volume":"17","author":"RL Tomko","year":"2018","unstructured":"Tomko RL, Jones JL, Gilmore AK, Brady KT, Back SE, Gray KM (2018c) N-acetylcysteine: a potential treatment for substance use disorders. Curr psychiatr 17:30\u201355","journal-title":"Curr psychiatr"},{"key":"5384_CR70","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.drugalcdep.2013.08.011","volume":"133","author":"P van der Pol","year":"2013","unstructured":"van der Pol P, Liebregts N, de Graaf R, Korf DJ, van den Brink W, van Laar M (2013) Facilitators and barriers in treatment seeking for cannabis dependence. Drug Alcohol Depend 133:776\u2013780","journal-title":"Drug Alcohol Depend"},{"key":"5384_CR71","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/00952990.2013.819362","volume":"40","author":"AM Weinstein","year":"2014","unstructured":"Weinstein AM, Miller H, Bluvstein I, Rapoport E, Schreiber S, Bar-Hamburger R, Bloch M (2014) Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study. Am J Drug Alcohol Abuse 40:16\u201322","journal-title":"Am J Drug Alcohol Abuse"},{"key":"5384_CR72","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.drugalcdep.2017.03.037","volume":"177","author":"L-T Wu","year":"2017","unstructured":"Wu L-T, Zhu H, Mannelli P, Swartz MS (2017) Prevalence and correlates of treatment utilization among adults with cannabis use disorder in the United States. Drug Alcohol Depend 177:153\u2013162","journal-title":"Drug Alcohol Depend"},{"key":"5384_CR73","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.drugalcdep.2018.07.001","volume":"191","author":"AM Wycoff","year":"2018","unstructured":"Wycoff AM, Metrik J, Trull TJ (2018) Affect and cannabis use in daily life: a review and recommendations for future research. Drug Alcohol Depend 191:223\u2013233","journal-title":"Drug Alcohol Depend"},{"key":"5384_CR74","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12888-018-1845-1","volume":"18","author":"C Yang","year":"2018","unstructured":"Yang C, Bosker FJ, Li J, Schoevers RA (2018) N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial. BMC Psychiatry 18:279","journal-title":"BMC Psychiatry"},{"key":"5384_CR75","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.neuint.2018.04.011","volume":"118","author":"R Yawalkar","year":"2018","unstructured":"Yawalkar R, Changotra H, Gupta GL (2018) Protective influences of N-acetylcysteine against alcohol abstinence-induced depression by regulating biochemical and GRIN2A, GRIN2B gene expression of NMDA receptor signaling pathway in rats. Neurochem Int 118:73\u201381","journal-title":"Neurochem Int"},{"key":"5384_CR76","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/j.euroneuro.2015.09.021","volume":"25","author":"E Zamberletti","year":"2015","unstructured":"Zamberletti E, Gabaglio M, Prini P, Rubino T, Parolaro D (2015) Cortical neuroinflammation contributes to long-term cognitive dysfunctions following adolescent delta-9-tetrahydrocannabinol treatment in female rats. Eur Neuropsychopharmacol 25:2404\u20132415","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"5384_CR77","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2307\/2531248","volume":"42","author":"Scott L. Zeger","year":"1986","unstructured":"Zeger SL, Liang K-Y (1986) Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42:121\u2013130","journal-title":"Biometrics"},{"key":"5384_CR78","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/acps.12862","volume":"137","author":"W Zheng","year":"2018","unstructured":"Zheng W et al (2018) N-acetylcysteine for major mental disorders: a systematic review and meta-analysis of randomized controlled trials. Acta psychiatrica Scandinavica 137:391\u2013400","journal-title":"Acta psychiatrica Scandinavica"},{"key":"5384_CR79","first-page":"435","volume":"72","author":"D Zhou","year":"2017","unstructured":"Zhou D, Li Y, Tian T, Quan W, Wang L, Shao Q, Fu LQ, Zhang XH, Wang XY, Zhang H, Ma YM (2017) Role of the endocannabinoid system in the formation and development of depression. Pharmazie 72:435\u2013439","journal-title":"Pharmazie"},{"key":"5384_CR80","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP (1983) The Hospital Anxiety and Depression Scale. Acta psychiatrica Scandinavica 67:361\u2013370","journal-title":"Acta psychiatrica Scandinavica"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-019-05384-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-019-05384-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-019-05384-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T19:10:29Z","timestamp":1604949029000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-019-05384-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,11]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["5384"],"URL":"https:\/\/doi.org\/10.1007\/s00213-019-05384-z","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,11]]},"assertion":[{"value":"23 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Rachel L. Tomko, Nathaniel L. Baker, Caitlyn O. Hood, Amanda K. Gilmore, Erin A. McClure, Lindsay M. Squeglia, Aimee L. McRae-Clark, and Susan C. Sonne declare that they have no conflict of interest. Kevin M. Gray has provided consultation to Pfizer, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}